Literature DB >> 413688

Influence of indomethacin on the systemic and pulmonary vascular resistance in man.

A Wennmalm.   

Abstract

1. Indomethacin, an inhibitor of the cyclo-oxygenase system that converts arachidonic acid into prostaglandins and related substances, was infused intravenously in 12 healthy volunteer subjects. 2. Systemic systolic and diastolic blood pressures and heart rate were recorded in all subjects, and in most of them also the systemic arteriovenous oxygen difference, the total oxygen uptake and the pulmonary arterial and wedge pressures. 3. The infusion of indomethacin was followed by a decreased cardiac output (from 7.3 +/- 0.3 to 6.3 +/- 0.3 litres/min) and an increased mean systemic blood pressure (from 92 +/- 1 to 102 +/- 1 mmHg), indicating an elevation of the total systemic vascular resistance (from 98 +/- 4 to 124 +/- 5 kPa 1(-1) s) by indomethacin. The ventilation and the pulmonary vascular resistance did not change after the infusion of indomethacin. 4. The results suggest that products formed by the cyclo-oxygenase system at rest exert a relaxing effect in certain parts of the systemic vascular bed, thereby lowering the systemic vascular resistance.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 413688     DOI: 10.1042/cs0540141

Source DB:  PubMed          Journal:  Clin Sci Mol Med        ISSN: 0301-0538


  16 in total

1.  Cyclooxygenase inhibition abolishes age-related differences in cerebral vasodilator responses to hypercapnia.

Authors:  Jill N Barnes; John E Schmidt; Wayne T Nicholson; Michael J Joyner
Journal:  J Appl Physiol (1985)       Date:  2012-03-22

2.  Hemodynamic and hormonal responses to 8-arginine-vasopressin in healthy man: effects of indomethacin.

Authors:  K Glänzer; B Prüssing; R Düsing; H J Kramer
Journal:  Klin Wochenschr       Date:  1982-10-01

3.  Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.

Authors:  J Watkins; E C Abbott; C N Hensby; J Webster; C T Dollery
Journal:  Br Med J       Date:  1980-09-13

4.  Arachidonic acid metabolites, hypertension and arteriosclerosis.

Authors:  P C Weber; W Siess; B Scherer; E Held; H Witzgall; R Lorenz
Journal:  Klin Wochenschr       Date:  1982-05-17

5.  [Reduced urinary prostaglandin E2-excretion and diminished responsiveness of plasma renin activity in patients with essential hypertension (author's transl)].

Authors:  B Scherer; E Held; H H Lange; P C Weber
Journal:  Klin Wochenschr       Date:  1979-06-01

6.  Reversal by prostaglandin E2 infusion of the effects of indomethacin on the excretion of nitrogenous compounds in the rat.

Authors:  D J Rowe; G Gedeon
Journal:  Br J Exp Pathol       Date:  1983-06

Review 7.  Do nonsteroidal anti-inflammatory drugs interfere with blood pressure control in hypertensive patients?

Authors:  K Radack; C Deck
Journal:  J Gen Intern Med       Date:  1987 Mar-Apr       Impact factor: 5.128

8.  Indomethacin does not attenuate the effects of hydralazine in normal subjects.

Authors:  S H Jackson; H Pickles
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 9.  Cardiovascular risks and benefits of perioperative nonsteroidal anti-inflammatory drug treatment.

Authors:  F Camu; C Van Lersberghe; M H Lauwers
Journal:  Drugs       Date:  1992       Impact factor: 9.546

10.  Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.

Authors:  L A Ferrara; M Mancini; T Marotta; F Pasanisi; M L Fasano
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.